You just read:

Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States

News provided by

Immune Pharmaceuticals Inc.

14 Jun, 2016, 07:30 ET